Atea Pharmaceuticals Inc. (AVIR) Social Stream



Atea Pharmaceuticals Inc. (AVIR): $3.25

0.09 (+2.85%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add AVIR to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#137 of 332

in industry

Featured Post From StockTwits About AVIR

$AVIR Currently there is not an effective antiviral treatment for COVID.

The 2 main drug groups to treat SARS-CoV-2 are :
• Agents targeting proteins or RNA of the virus or
• Agents interfering with proteins or biological processes in the host that support the virus.

The main drug groups include
• Inhibitors of viral entry (convalescent plasma, monoclonal antibodies, etc)
• Inhibitors of viral proteases (lopinavir/ritonavir, PF-07321332, PF-07304814, GC376)
• Inhibitors of viral RNA (remdesivir, favipiravir, molnupiravir, AVIR AT-527, merimepodib, PTC299)
• Inhibitors of host proteins supporting virus (plitidepsin, fluvoxamine, ivermectin)
• Agents supporting host natural immunity (Interferons).

Monoclonal antibodies are seem to be the most effective treatment for COVID at the moment.

Results of phase trials are waited to learn whether or not the newer agents such as molnupiravir, PF-07321332, PF-07304814, plitidepsin and AT-527 are effective.

https://www.docwirenews.com/abstracts/antiviral-treatment-of-covid-19-an-update/
StrategyDD, published August 16, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!